VIC-008 represents a new approach to targeted tumor immunotherapy. It enhances tumor-specific CD8+ T cell responses against cancer by tagging tumors with proteins that active immune cells and induce uptake and processing of tumor-specific antigens. VIC-008 is a recombinant fusion protein that combines a high-affinity single chain antibody fragment (scFv) directed against human mesothelin with a full Mycobacterium tuberculosis heat shock protein 70 (MtbHsp70). The two proteins are genetically fused via a short linker between the C-terminus end of the scFv and the N-terminus of MtbHsp70. Small doses of VIC-008 have shown improved survival in normal immune mouse models of both ovarian cancer and mesothelioma. In mechanistic studies the fusion protein has shown the ability to promote uptake of the cancer cells by antigen presenting cells and to facilitate cross presentation of different cancer antigens to the immune system. The candidate has now completed small-animal proof of concept studies and is ready for further preclinical development. VIC has recently engaged a large pharma partner for further development of this candidate for treatment of ovarian cancer.